Background: Due to Regular blood transfusions and Desferrioxamine therapy, beta-thalassemic patients can live for over 30 years. It is becoming increasingly common for liver diseases to cause mortality and morbidity in these patients. Chelation compliance has improved with the recent addition of the oral single-dose therapy Deferasirox (DFX). This study will investigate the impact of iron therapy on liver function tests in BMT patients.

Methodology: The patients enrolled in the study were HBV negative and treated with DFO and DFX after BTM. The LFTs include alanine transferase, Albumin, serum bilirubin and aspartate transferase. Sixty patients with Beta-thalassemia were followed every six months for serum ferritin concentrations.

Results: Therapy with Desferrioxamine significantly decrease serum ferritin levels inbeta-thalassemia patients and isconcerned with high reduction in serumalanine transaminase and serum aspartate transaminase. Albumin concentrations remain the same in DFX treatment. Association between serum ferritin levels ALT and AST levels were found. There is a negative correlation between serum ferritin concentration and ALT.

Conclusion: Patients with Hepatitis negative having thalassemia with iron overload may have some liver function impairment. As a result of DFX treatment, AST, ALP and ALT levels were significantly reduced.